Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.

Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists.

Stoch SA, Parker RA, Chen L, Bubley G, Ko YJ, Vincelette A, Greenspan SL.

J Clin Endocrinol Metab. 2001 Jun;86(6):2787-91.

PMID:
11397888
2.

Therapy Insight: osteoporosis during hormone therapy for prostate cancer.

Smith MR.

Nat Clin Pract Urol. 2005 Dec;2(12):608-15; quiz 628. Review.

PMID:
16474548
3.

Osteoporosis and obesity in men receiving hormone therapy for prostate cancer.

Smith MR.

J Urol. 2004 Nov;172(5 Pt 2):S52-6; discussion S56-7. Review.

PMID:
15535444
4.

Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.

Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR.

Cancer. 2004 Mar 1;100(5):892-9. Review.

5.
6.

[Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].

Kudlacek S, Puntus T.

Wien Med Wochenschr. 2012 Sep;162(17-18):380-5. doi: 10.1007/s10354-012-0106-z. Epub 2012 Aug 9. Review. German.

PMID:
22875632
7.

Androgen deprivation therapy for prostate cancer: new concepts and concerns.

Smith MR.

Curr Opin Endocrinol Diabetes Obes. 2007 Jun;14(3):247-54. Review.

8.

The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK.

Rosario DJ, Davey P, Green J, Greene D, Turner B, Payne H, Kirby M.

World J Urol. 2016 Dec;34(12):1601-1609. Epub 2016 Apr 20. Review.

10.

Bone-targeted therapy in prostate cancer.

Saad F.

EJC Suppl. 2013 Sep;11(2):257-9. doi: 10.1016/j.ejcsup.2013.07.038. Review. No abstract available.

Supplemental Content

Support Center